Together, these results indicate thatthe Akt1/2–Nanog pathway is critical for maintenance of sarcoma CSCs andspheroid-forming cells, supporting further exploration of this pathway as atherapeutic target in sarcoma. This evidence concerns the gene AKT1 and sarcoma.